Evolocumab (Repatha), a novel first-in-class treatment to lower cholesterol
May 22, 2015 – The European Medicines Agency (EMA) has recommended authorising Evolocumab (Repatha) as treatment to lower high levels of cholesterol in the blood of people who are unable to control their cholesterol despite taking optimal doses of statins …
Evolocumab (Repatha), a novel first-in-class treatment to lower cholesterol Read more »